预约演示
更新于：2025-02-08
Ergoloid Mesylates
甲磺酸二氢麦角碱
更新于：2025-02-08
概要
基本信息
药物类型 小分子化药 |
别名 co-dergocrine mesilate、Co-dergocrine Mesylate、co-dergocrine methanesulfonate + [29] |
作用机制 α-adrenergic receptor拮抗剂(α-肾上腺素能受体家族拮抗剂) |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (1953-11-05), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
2
项与 甲磺酸二氢麦角碱 相关的临床试验NCT05030129
An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in Adult Males With Fragile X Syndrome
ChiCTR-IPR-17011155
Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease
100 项与 甲磺酸二氢麦角碱 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸二氢麦角碱 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸二氢麦角碱 相关的专利（医药）
登录后查看更多信息
1,251
项与 甲磺酸二氢麦角碱 相关的文献（医药）2025-01-02Food Additives and Contaminants Part A-Chemistry Analysis Control Exposure & Risk Assessment
Contaminants and residues have varied distributions in large volumes of wheat
Article
作者: Timofeiev, Valentina ; Huang, Mei ; Serda, Maria ; Tran, Michael ; Drul, Dainna ; Gaba, Don ; Tittlemier, Sheryl A. ; Roscoe, Mike ; Blagden, Richard ; Chan, Jason ; Richter, Anja
Analysis of bulk wheat consignments for naturally-occurring contaminants and residues from plant protection products is common, and helps manage potential health risks to consumers. The heterogeneous distribution of some mycotoxins in wheat has been described, however the distribution of other contaminants and residues has not yet been reported. This study characterized distributions of deoxynivalenol, ochratoxin A, ergot alkaloids, cadmium, and glyphosate in nine large consignments of wheat by analysing composite samples representing sub-lots prepared from increments obtained during the entire loading process. The widest span of concentrations within a consignment occurred for ochratoxin A (<0.5-22.9 µg/kg) and ergot alkaloids (0.009-0.486 mg/kg), followed by deoxynivalenol (<0.05-0.76 mg/kg) and glyphosate (<0.3-5.01 mg/kg), and then cadmium (0.022-0.102 mg/kg). Experimental semivariograms were plotted to model the spatio-temporal correlation of analytes within consignments during loading. Analyses demonstrated that distributions of contaminants and residues within a particular consignment differed, and that distributions of a particular contaminant or residue differed among consignments. The results indicate that sampling during only a portion of a loading or unloading process can result in a composite sample that is not representative of the consignment and thus increase the risk of misclassifying a consignment as compliant.
2024-10-01CANADIAN JOURNAL OF VETERINARY RESEARCH-REVUE CANADIENNE DE RECHERCHE VETERINAIRE
Effects of exposure to chronic ergot alkaloids on phenylephrine contractile response of maternal pedal artery, umbilical artery, and umbilical vein in pregnant ewes.
Article
作者: Blakley, Barry ; Desai, Kaushik ; Yonpiam, Rossalin ; Al-Dissi, Ahmad
Ergot alkaloids are known to cause devastating effects in livestock. The objectives of this study were to evaluate the effects of prolonged ergot exposure on selected vasculature in pregnant sheep and to examine the role of alpha-1 adrenergic receptors in mediating these effects. Twelve 60-day pregnant sheep were randomly placed into control and exposure groups (n = 6/group). Ergot-contaminated feed pellets were given orally once a day for 45 d to the exposure group [46.6 μg/kg body weight (BW) total ergot alkaloids]. The control group (Ctl) received ergot-free pellets. The maternal pedal artery from the left hindlimb and the umbilical artery and vein were dissected and mounted in a tissue bath. The vascular contractile response to a cumulatively increasing dose of phenylephrine (PE) in the exposure group (Exp) was compared with the control groups. Chronic exposure to ergot alkaloids resulted in a 70.6% and 91.3% increase in PE contractile response in the umbilical artery (Ctl EC50 = 3.962 × 10-6; Exp EC50 = 1.161 × 10-6, P < 0.0001) and the umbilical vein (Ctl EC50 = 7.889 × 10-6; Exp EC50 = 6.801 × 10-7, P < 0.0001), respectively, but there was no increase in the pedal artery (P = 0.3927), when compared to the control group. Fetal weight in the ergot-exposed group was significantly lower than in the control group (Ctl 3.3 ± 0.17 kg; Exp 2.07 ± 0.13 kg, P = 0.0002). The increase in contractile response in the umbilical vein may result in decreased blood supply to the fetus causing decreased fetal weight. Negative impact was seen at significantly lower levels of ergot alkaloids than what is currently allowed by Canadian standards, which suggests that these limits should be reevaluated to ensure livestock safety.
2024-05-01Neuropharmacology
DHEC mesylate attenuates pathologies and aberrant bisecting N-glycosylation in Alzheimer's disease models
Article
作者: Xue, Yue ; Wang, Yue ; Cao, Yiming ; Gao, Xiangdong ; Chen, Song ; Huang, Hongfei
Tremendous progress has been made to develop the therapy of Alzheimer's disease (AD). Existing several anti-AD remedies, with certain limitations, are far from adequate. Evidence suggests that dihydroergocristine (DHEC) mesylate, one of the main components of Ergoloid mesylates, can reduce the production of amyloid-β in vitro. However, the therapeutic effect of DHEC mesylate in AD and its underlying mechanism are still largely unknown. Herein, we characterized the pharmacological effect of DHEC mesylate in AD and found that the spatial memory disorders and Alzheimer-type pathologies were alleviated by DHEC mesylate administration. Moreover, we demonstrated that DHEC mesylate improved aberrant bisecting N-glycosylation, which was identified as a potential biomarker of AD. We further explored the underlying mechanism and confirmed that DHEC mesylate protected against AD via AMPK and ERK signaling, in which, AMPK was the dominant down-stream molecule of DHEC mesylate. In summary, our findings provide foundations for development of DHEC mesylate as a therapeutic approach for AD.
3
项与 甲磺酸二氢麦角碱 相关的新闻（医药）2022-08-30
2022-08-18
2022-07-27
100 项与 甲磺酸二氢麦角碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头痛 | 中国 | 1999-08-13 | |
| 痴呆 | 美国 | 1953-11-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 15 | Matching placebo for 5-Hydroxytryptophan+Ergoloid Mesylates (Ergoloid Mesylates (EM)) | 鬱鏇夢鑰艱範網觸範鏇(醖夢壓簾簾鹹鹹觸製蓋) = 觸繭衊蓋鏇壓鬱積窪廠 範鬱獵糧艱糧醖醖構鬱 (蓋窪淵艱廠網築鹽鬱遞, 壓醖顧壓遞積鹽觸醖壓 ~ 範鏇窪遞膚襯獵艱網醖) 更多 | - | 2024-09-19 | ||
(Ergoloid Mesylates (EM) and 5-hydroxytryptophan (5-HTP)) | 鬱鏇夢鑰艱範網觸範鏇(醖夢壓簾簾鹹鹹觸製蓋) = 齋鹽構壓鹹鹽構築選觸 範鬱獵糧艱糧醖醖構鬱 (蓋窪淵艱廠網築鹽鬱遞, 獵淵窪顧淵憲選鬱鬱願 ~ 衊廠構網壓簾艱顧願繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用